摘要
目的探讨异丙托溴铵联合布地奈德及沙丁胺醇治疗慢性阻塞性肺疾病急性加重期(AECOPD)的临床疗效及安全性。方法将本院收治的AECOPD患者118例随机分为2组,对照组59例实施布地奈德联合沙丁胺醇雾化吸入治疗,观察组59例以异丙托溴铵联合布地奈德及沙丁胺醇雾化吸入治疗,比较2组治疗效果。结果观察组临床疗效显著高于对照组(P<0.05);治疗前,2组血气指标、肺功能指标无显著差异(P>0.05),治疗后,观察组均显著优于对照组(P<0.05);观察组憋喘、咳嗽、哮鸣音、湿啰音等症状消失时间均显著短于对照组(P<0.05);2组不良反应发生率无显著差异(P>0.05)。结论采用异丙托溴铵联合布地奈德及沙丁胺醇对AECOPD患者的治疗效果显著,能显著改善患者症状及肺功能,且具有较高的安全性。
Objective To investigate the clinical efficacy and safety of ipratropium bromide combined with budesonide and salbutamol in the treatment of acute exacerbations of chronic obstructive pulmonary disease(AECOPD).Methods A total of 118 patients with AECOPD admitted to our hospital were divided into two groups according to the randomized principle.The control group(n=59)was treated with budesonide and inhalation of salbutamol,and the observation group(n=59)was treated with ipratropium bromide combined with budesonide and salbutamol inhalation.Therapeutic effects of the two groups were compared.Results The clinical efficacy of the observation group was significantly higher than that of the control group(P<0.05);before treatment,there was no significant difference in blood gas index and lung function index between the groups(P>0.05),but the observation group was significantly better than the control group after treatment(P<0.05).The disappearance time of symptoms such as asthma,cough,wheezing,and wet rales in the observation group was significantly shorter than that in the control group(P<0.05),the incidence of adverse reactions in the two groups showed no significant difference(P>0.05).Conclusion Ipratropium bromide combined with budesonide and salbutamol is of great significance in efficacy in the treatment of AECOPD.It can improve the symptoms and lung function of patients,and has a higher safety.
作者
张军战
ZHANG Junzhan(Department of Cardiology,Baishui County Hospital,Weinan,Shaanxi,715600)
出处
《实用临床医药杂志》
CAS
2019年第3期57-59,共3页
Journal of Clinical Medicine in Practice
关键词
异丙托溴铵
布地奈德
沙丁胺醇
慢性阻塞性肺疾病急性加重期
肺功能指标
ipratropium bromide
budesonide
salbutamol
acute exacerbations of chronic obstructive pulmonary disease
pulmonary function indicators
